Department of Radiology and Nuclear Medicine, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, 625 00, Czech Republic.
Department of Biophysics, Faculty of Medicine, Masaryk University, Brno, 625 00, Czech Republic.
Cardiovasc Intervent Radiol. 2022 Jun;45(6):873-878. doi: 10.1007/s00270-022-03097-z. Epub 2022 Feb 25.
To prove feasibility and safety of percutaneous endoluminal radiofrequency ablation (eRFA) using a monopolar approach in treatment of occluded biliary stent in malignancy.
The study included 11 patients with occluded biliary metal stent that had been implanted due to malignant biliary obstruction. All underwent metal stent recanalization by percutaneous eRFA in monopolar setting. Sixteen eRFA procedures were performed under fluoroscopic guidance with an EndoHPB 8F radiofrequency ablation catheter. The effect of stent recanalization was assessed based upon change from pre- to post-procedural diameter of the patent lumen of the metal stent (Wilcoxon test), primary and secondary stent patency (compared by log-rank test), catheter-free period, and overall survival. Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTCEA) 4.0.
Recanalization of the metal stent by monopolar radiofrequency ablation was successful in all 11 patients. Diameter of the patent lumen of the stent significantly widened after the eRFA inside the stent (median 2 vs. 7 mm, p = 0.003). Grade 1 complications were observed in one-third of procedures. Median stent patency after recanalization by eRFA was non-inferior to primary metal stent patency (154 vs. 161 days, p = 0.27). Median catheter-free survival and overall survival after stent recanalization were 149 and 210 days, respectively.
Endoluminal radiofrequency ablation in monopolar setting was shown to be a feasible and safe method for recanalization of occluded biliary metal stents.
Level 4, Case Series.
证明经皮腔内单极射频消融(eRFA)治疗恶性胆道梗阻金属支架内再发狭窄的可行性和安全性。
本研究纳入了 11 例因恶性胆道梗阻而植入金属支架的胆管闭塞患者。所有患者均采用经皮腔内 eRFA 单极方式进行金属支架再通。在透视引导下,使用 EndoHPB 8F 射频消融导管进行 16 次 eRFA 操作。根据金属支架通畅腔的直径从术前到术后的变化(Wilcoxon 检验)、初次和继发性支架通畅(对数秩检验比较)、无导管期和总生存期来评估支架再通效果。根据不良事件通用术语标准(CTCEA)4.0 评估不良事件。
11 例患者的金属支架均成功通过单极射频消融再通。支架内 eRFA 后,支架通畅腔的直径明显变宽(中位数 2 毫米比 7 毫米,p = 0.003)。三分之一的操作中观察到 1 级并发症。eRFA 再通后的支架通畅中位时间与初次金属支架通畅时间无差异(154 天比 161 天,p = 0.27)。支架再通后无导管生存时间和总生存时间的中位数分别为 149 天和 210 天。
腔内单极射频消融被证明是一种可行且安全的方法,可用于再通阻塞的胆管金属支架。
4 级,病例系列。